December 2nd 2024
If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Topical tacrolimus clears peristomal PG
February 21st 2005Local treatment with the topical immunomodulator tacrolimus 0.1 percent ointment (Protopic, Fujisawa) may be a useful adjunct in the management of pyoderma gangrenosum (PG), and can some times be used successfully as monotherapy, perhaps particularly for the treatment of peristomal disease, said David Fivenson, M.D.
Palmoplantar pustulosis merits greater research attention
February 20th 2005Palmoplantar pustulosis (palmoplantar pustular psoriasis) presents a frustrating therapeutic challenge to clinicians and a disabling disease for patients deserving of greater research interest from the global dermatology community, says Robert J.G. Chalmers, M.B.B.S.
Palmoplantar pustulosis merits greater research attention
February 20th 2005Palmoplantar pustulosis (palmoplantar pustular psoriasis) presents a frustrating therapeutic challenge to clinicians and a disabling disease for patients deserving of greater research interest from the global dermatology community, says Robert J.G. Chalmers, M.B.B.S.